Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
NiKang Therapeutics, Inc.
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
BeOne Medicines
Eli Lilly and Company
Arcus Biosciences, Inc.
Accent Therapeutics
Seagen Inc.
Tizona Therapeutics, Inc
Normunity AccelCo, Inc.
Eli Lilly and Company
NiKang Therapeutics, Inc.
Institute of Cancer Research, United Kingdom
SystImmune Inc.
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Novartis
OncoNano Medicine, Inc.
NeoTX Therapeutics Ltd.
Bolt Biotherapeutics, Inc.
Mersana Therapeutics
Rondo Therapeutics
NiKang Therapeutics, Inc.
Nurix Therapeutics, Inc.
Exelixis
Adcentrx Therapeutics
Xencor, Inc.
Incyte Corporation
Lyell Immunopharma, Inc.
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Theratechnologies
Exelixis
Seagen Inc.
Compugen Ltd
Sotio Biotech Inc.
Novartis
Sunnybrook Health Sciences Centre
Vincerx Pharma, Inc.
AstraZeneca
Light Chain Bioscience - Novimmune SA
Xencor, Inc.
Adlai Nortye Biopharma Co., Ltd.